Artes Biotechnology  GmbH  
HomeAbout ARTESTechnologiesOfferProductsContact   
         
  Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services

Artes Biotechnology GmbH | Contract R&D Services
ARTES Biotechnology GmbH

Biotechnological Processes and Products for Today and Tomorrow
ARTES Biotechnology is a well established development partner for recombinant protein production. Several bio-pharmaceutical products and industrial enzymes have been successfully introduced worldwide in the market by our clients and licensees.

ARTES Biotechnology delivers safe, robust and cost efficient protein production based on microbial cell lines including yeast (Hansenula polymorpha, syn. Pichia angusta) and bacteria (E. coli).

Our unique virus like particle (VLP) platform is applied for development of safe and affordable vaccines.

ARTES´ proprietary technologies ensure freedom-to-operate and reliable, competitive production. WHO recommendation, international registration, FDA approval and GRAS certification are part of the track record achieved in our international collaborations.

Large scale manufacturing and full analytics in accordance with cGMP guidelines are warranted in collaboration with a network of industrial partners.

Today

A wide range of processes and products is available in our portfolio for immediate technology transfer.

Tomorrow

New cell lines and processes for your product of interest are developed specifically to meet your demands.

Artes Biotechnology GmbH | Contract R&D Services.

 
   news
17.02.2014 EU Research Project "Nano3Bio" has Started – "Huge Potential" through Biotechnology
ARTES Biotechnology GmbH is part of the international consortium
While the oil is slowly but surely running out, renewable resources are becoming increasingly important. In future, the biological production of raw materials has to play an even greater role to meet the needs in an environmentally friendly manner. An international consortium of researchers and companies now rises to this challenge. Its goal is the biotechnological production of so-called chitosans, which are used as raw materials for medicine, agriculture, water treatment, cosmetics, paper and textile industries as well as many other fields of application. To tap this potential, the European Commission supports the research project "Nano3Bio" with a total of almost 9 million Euros up to 2017. In addition to the experts from ARTES, universities and research institutes as well as companies from Belgium, Denmark, France, Germany, India, The Netherlands, Spain and Sweden are involved. They recently met to kick off the project in Münster, Germany.
"The Nano3Bio project is making a scientific dream come true, because this strong consortium will be able to achieve a breakthrough from basic research to the biotechnological production of chitosans", says Professor Dr. Bruno Moerschbacher, biologist at the University of Münster and coordinator of the project.

 

 
Top of Page
  Copyright by Artes Biotechnology GmbH 2013